AU2005210006B2 - Screening assays - Google Patents

Screening assays Download PDF

Info

Publication number
AU2005210006B2
AU2005210006B2 AU2005210006A AU2005210006A AU2005210006B2 AU 2005210006 B2 AU2005210006 B2 AU 2005210006B2 AU 2005210006 A AU2005210006 A AU 2005210006A AU 2005210006 A AU2005210006 A AU 2005210006A AU 2005210006 B2 AU2005210006 B2 AU 2005210006B2
Authority
AU
Australia
Prior art keywords
rna
mrna
secondary structure
oligonucleotide
hur
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005210006A
Other languages
English (en)
Other versions
AU2005210006A1 (en
Inventor
Manfred Auer
Joerg Hackermueller
Markus Jaritz
Nicole-Claudia Meisner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2005210006A1 publication Critical patent/AU2005210006A1/en
Application granted granted Critical
Publication of AU2005210006B2 publication Critical patent/AU2005210006B2/en
Priority to AU2008261191A priority Critical patent/AU2008261191A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
AU2005210006A 2004-02-05 2005-02-04 Screening assays Ceased AU2005210006B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008261191A AU2008261191A1 (en) 2004-02-05 2008-12-23 Screening assays

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US54231504P 2004-02-05 2004-02-05
US60/542,315 2004-02-05
US56046404P 2004-04-08 2004-04-08
US60/560,464 2004-04-08
PCT/EP2005/001168 WO2005075637A2 (en) 2004-02-05 2005-02-04 Screening assays

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008261191A Division AU2008261191A1 (en) 2004-02-05 2008-12-23 Screening assays

Publications (2)

Publication Number Publication Date
AU2005210006A1 AU2005210006A1 (en) 2005-08-18
AU2005210006B2 true AU2005210006B2 (en) 2008-09-25

Family

ID=34841137

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2005210006A Ceased AU2005210006B2 (en) 2004-02-05 2005-02-04 Screening assays
AU2008261191A Abandoned AU2008261191A1 (en) 2004-02-05 2008-12-23 Screening assays

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2008261191A Abandoned AU2008261191A1 (en) 2004-02-05 2008-12-23 Screening assays

Country Status (10)

Country Link
EP (1) EP1713913A2 (https=)
JP (1) JP2007521813A (https=)
KR (1) KR20060135798A (https=)
CN (1) CN1918294A (https=)
AU (2) AU2005210006B2 (https=)
BR (1) BRPI0507480A (https=)
CA (1) CA2554218A1 (https=)
IL (1) IL176991A0 (https=)
RU (1) RU2006131550A (https=)
WO (1) WO2005075637A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011062166A1 (ja) * 2009-11-17 2011-05-26 武田薬品工業株式会社 Ｒｎａの二次構造の動態を予測する方法
JP2013519869A (ja) 2010-02-10 2013-05-30 ノバルティス アーゲー 筋肉成長のための方法および化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004099411A1 (en) * 2003-05-07 2004-11-18 Novartis Ag A method for dissecting the rna secondary structure dependence of rna-ligand interactions

Also Published As

Publication number Publication date
AU2005210006A1 (en) 2005-08-18
EP1713913A2 (en) 2006-10-25
BRPI0507480A (pt) 2007-07-17
WO2005075637A2 (en) 2005-08-18
KR20060135798A (ko) 2006-12-29
JP2007521813A (ja) 2007-08-09
AU2008261191A1 (en) 2009-01-22
RU2006131550A (ru) 2008-03-10
WO2005075637A3 (en) 2005-11-10
IL176991A0 (en) 2006-12-10
CA2554218A1 (en) 2005-08-18
CN1918294A (zh) 2007-02-21

Similar Documents

Publication Publication Date Title
Meisner et al. mRNA openers and closers: modulating AU‐rich element‐controlled mRNA stability by a molecular switch in mRNA secondary structure
Lyu et al. RNA G-quadruplexes (rG4s): genomics and biological functions
Keam et al. tRNA-derived RNA fragments associate with human multisynthetase complex (MSC) and modulate ribosomal protein translation
Jones et al. Challenges and perspectives for structural biology of lncRNAs—the example of the Xist lncRNA A-repeats
Bevilacqua et al. Thermodynamic analysis of an RNA combinatorial library contained in a short hairpin
US8710199B2 (en) Signal activated molecular delivery
Semrad Proteins with RNA chaperone activity: A world of diverse proteins with a common task—impediment of RNA misfolding
JP2001103975A (ja) モジュレートアプタマー及びこれを用いた標的タンパク質の検出方法
Ma et al. ADAR1 promotes robust hypoxia signaling via distinct regulation of multiple HIF‐1α‐inhibiting factors
Yang et al. A general strategy exploiting m5C duplex-remodelling effect for selective detection of RNA and DNA m5C methyltransferase activity in cells
Vlasschaert et al. Selection preserves Ubiquitin Specific Protease 4 alternative exon skipping in therian mammals
Monforte et al. RNA folding during transcription by Escherichia coli RNA polymerase analyzed by RNA self-cleavage
Xiao et al. Diverse reagent scaffolds provide differential selectivity of 2′-OH acylation in RNA
Luo et al. Iso-FRET: an isothermal competition assay to analyze quadruplex formation in vitro
FOeRCH et al. Modulation of msl-2 5′ splice site recognition by Sex-lethal
Guo et al. Mapping circular RNA structures in living cells by SHAPE-MaP
Sosic et al. Mechanisms of HIV-1 nucleocapsid protein inhibition by Lysyl-Peptidyl-anthraquinone conjugates
AU2005210006B2 (en) Screening assays
Hashem et al. Hybrid Oligomer Duplexes Formed with Phosphorothioate DNAs: CD Spectra and Melting Temperatures of S-DNA⊙ RNA Hybrids Are Sequence-Dependent but Consistent with Similar Heteronomous Conformations
ES3002882T3 (en) Method for screening compound for controlling rna function
Kierzek Binding of short oligonucleotides to RNA: studies of the binding of common RNA structural motifs to isoenergetic microarrays
Shang et al. siRNAs target sites selection of ezrin and the influence of RNA interference on ezrin expression and biological characters of osteosarcoma cells
Bhaskaran et al. Structural dynamics of a mitochondrial tRNA possessing weak thermodynamic stability
Duan et al. Interpreting Oligonucleotide Microarray Data To Determine RNA Secondary Structure: Application to the 3 ‘End of Bombyx mori R2 RNA
Romero Agosto et al. DMS‐MapSeq Analysis of Antisense Oligonucleotide Binding to lncRNA PANDA

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired